2019 was a good year for the pharma industry, even as questions on value kept coming; but 2020 brought a pandemic that raised an “all hands on deck” attitude as well as business challenges.

First-quarter 2020 earnings reports are coming out, the stock market remains volatile and much of the world is still on lockdown. In this challenging environment, there are business opportunities abound, “but investors are taking a hard look at their checkbooks,” Keith Bliss, managing partner and CEO of iQ Capital, told BioSpace.

While employees of Cambridge, Massachusetts-based Biogen who attended a management meeting in Boston tested positive for COVID-19, numerous biopharma organizations are cancelling or postponing activities that involve large groups of people.

Companies from across the globe provide updates on their business and pipeline progress.

BioSpace’s Biotech Bay Hotbed includes biotech and biopharmaceutical companies that are located in San Francisco and Northern California. The companies listed below are the top ten companies headquartered in Biotech Bay based on 2018 revenue.

A2A Pharmaceuticals Inc. named Dr. Sotirios G. Stergiopoulos as president and CEO.

Richard Klinghoffer, Ph.D., was named CEO of Presage Biosciences.

James (Jim) Robinson is named president and CEO of Alkermes Inc. Robinson joined Alkermes from Astellas US LLC, where he served as president, Americas Operations with responsibility for the company’s […]

R&D success and M&A activity loom as large swing factors for the bio sector in 2017 with the regulatory arena potentially at its most amenable for years.

This chart shows the 2016 and 2015 revenue and R&D figures for some of the world’s leading biotech and biopharma companies.